on media to dispute sofosbuvir price considered as scandalous, while compliant with local and international benchmark Health Market Pricing Legislation to control its price. Under tremendous media, political and administrative pressure, the manufacturer accepted significant price decrease, early entry agreement in France and later in most EU countries. Following this saga, to ensure drug budget will be used under certain (DES) medical plan, in 2015, Health Canada approved budget expenditure for HCV.

CONCLUSION: This case highlights limit of current pricing policies which are unable to match affordability and drug prices. Even if sofosbuvir case confirms the inability of cost-effectiveness analysis to address affordability issue, budget impact decision making will become more and more critical in the future.

PHP340

IS ONCOLOGY DRUG FINANCIAL TOXICITY A SPECIFIC US ISSUE?
Chouaid C1, Truter I2, Brand M3, La Cock P4
1Centre Hospitalier Intercommunal, DHU-ATVB, Créteil, France, 2Créa-Ceutical, Paris, France, 3Créa-Ceutical, Krakow, Poland, 4Université Aix Marseilles, Marseilles, France

BACKGROUND: Cancer imposes enormous financial burden to society. Direct medical costs represented at around $1 trillion across European (EU) countries (2009) and $887 billion in the United States (US) (2011). The concept of “financial toxicity” has been first reported by US academic oncologists, Zafar and Abernathy in 2013. It refers to financial distress linked to out-of-pocket payments of costly oncology drugs (OD). This critical concept led to the development of a patient-reported outcome questionnaire by de Souza et al. This conceptual research aimed to address aspects of oncology drug financial toxicology (ODFT) and how the US and European (EU) patients responded to the high costs towards the expensive treatments needed to affect patient’s quality of life and treatment adherence. In US, ODFT is related to the positioning in specialty care tier (fourth or fifth tier), leaving a high co-pay for the patients. Moreover, 13% of the US population is uninsured (2013). This issue is not new; in 2007, a study reported that 16% of oncologist did not propose expensive drugs to some patients based on their perception of patient affordability. In EU, the countries differ within Spain, Greece, France the different access levels and reimbursement levels of patients from ODFT. Patients are either 100% covered for all reimbursed drugs (France, UK, Germany, Spain, Italy), or drugs are not recommended/reimbursed and then not proposed to the patients nor requested by the patients. The level of availability and access to the health procurement at national levels and at the country levels will high access to cancer drugs seen in France and Germany, while more restricted access seen in Spain, Italy and the UK.

CONCLUSIONS: EU inhabitants will remain protected from ODFT as long as reimbursement process remains an on/off system (100% or 0% coverage) and off-reimbursement use is exceptional. ODFT will remain specific to the US and possibly to emerging countries.

PHP341

THE SOUTH AFRICAN GUIDELINES FOR PHARMAECO-ECONOMIC SUBMISSIONS: A REVIEW IN CONTEXT OF EXISTING LEGISLATION AND CHALLENGES TO IMPLEMENTATION
McGee S1, Truter P, Brand M2, La Cock P3
1ISPQR South Africa Chapter, Pretoria, South Africa, 2Nelson Mandela Metropolitan University, Port Elizabeth, South Africa, 3BrandTech Healthare Technology Consulting, Johannesburg, South Africa, 4Design Process, Cape Town, South Africa

BACKGROUND: The South African Pharmacoeconomic Guidelines were published in February 2013, with the intention for application to newly approved medicines in the public sector. However, uptake has been poor and the number of submissions is negligible. OBJECTIVES: This study aims to examine the pharmacoeconomic guidelines in the context of existing legislation, policy and incentives in the private sector in South Africa to make explicit the poor uptake and consider the implications of not implementing the guidelines. METHODS: A review of existing legislation regulating reimbursement of medicines in the private sector was undertaken in relation to the implementation of the guidelines, as well as interviews with key stakeholders in the pharmacoeconomic industry, ministry of health, health insurance industries to understand attitudes to and challenges to adopting the guidelines submission criteria and results. RESULTS: Existing legislation means that results of pharmacoeconomic submissions are not enforceable – funders are not required reimburse for products should the ministry of health evaluations process deem them cost-effective. Pharmaceutical companies are thus at risk of a negative finding on reimbursement with no assurance that a positive finding will improve reimbursement for new products. As submission is currently not mandatory, this is something they will be more willing to do. The level of strict application or flexibility within the requirements of the guidelines is also not clear. CONCLUSIONS: Uptake and engagement with the South African Pharmacoeconomic guidelines has been poor, with submissions formally evaluated since the guidelines were finalised. Several existing policy and legislative barriers exist which make the success of these guidelines in the current environment unlikely. Building capacity for submitting analyses as well as within the ministry of health to evaluate submissions will be critical.

PHP342

NEED FOR NEW PHARMACOECONOMICS POLICY FOR REGULATING PRICES OF MEDICAL DEVICES IN INDIA
Somi P, Gupta SK
1Dhruv Institute of Pharmaceutical Sciences & Research, Delhi, India, 2Delhi Institute of Pharmaceutical Sciences and Research, University of Delhi, Delhi, India

In India, medical device industry is a multi-product industry covering the entire gamut from disposable gloves and syringes to high-end machines like CT scans and MRI. There has been a rapid growth with a Compound Annual Growth Rate (CAGR) of 15%. Over 75% of medical devices market is dependent on imports, mostly by multinationals that have no manufacturing facility in India. According to a survey conducted by us, the disposables ($1.57 billion), consumables ($0.83 billion) and surgical instruments ($0.06 billion) market depends on around 40-50% of imported products while the medical electronics ($1.57 billion), hospital equipments ($0.39 billion), implants ($0.20 billion) and diagnostics ($0.09 billion) categories on around 85-90%. Due to more dependency on imported products as well as absence of regulations for prices in India, doctors, hospitals and retailers charged the patients almost three to four times for certain devices e.g. Drug delivery pumps, which are manufactured by Abbott imported at $60 and sold at $2000, a markup of over 25% and that manufactured by Medtronic imported at $485 and sold at $2600, a mark-up of more than 400%. Recognising this policy deficit, the Indian government is working on new guidelines for efficient health care delivery. In India, the medical device industry is multi-product industry covering the entire gamut from disposable gloves and syringes to high-end machines like CT scans which will also include the above mentioned devices and the same will be presented in this presentation along with our survey data.

PHP343

PRICING AND REIMBURSEMENT POLICIES OF TURKEY AND UKRAINE
Atikeler K1, Pinzacho O2
1Hacettepe University, Ankara, Turkey, 2Danylo Halytsky Lviv National Medical University, Lviv, Ukraine

Recently, the need for health services has increased gradually and the limitations in sources allocated for this area have been recognized. According to Danzon (2000), the multi-faceted system that includes high public prescription cycle, high expenses and fiscal constraints to healthcare systems is the way to control costs. Pricing and reimbursement methods are the main method to increase the benefit in the health sector. Turkey has been one of the countries that is trying to change the pharmaceutical policies in Turkey. It was detected that the pharmaceutical pricing in Turkey has been performed on the basis of the reference pricing system that takes Italy, Spain and Greece as a reference. In case of re-imbursement, the re-imbursement process are determined by SSI. In Ukraine there are margin control and reference pricing methods for only the medicines that may be public purchased and are included in the National list of medicines and the list of medicines “On the purchase of medicines without health insurance”. These methods have been developed in the countries that have high cost of healthcare treatment. The reference pricing for medicines and medical products, purchased by the state and local budgets reference pricing is implemented for medicines, which are included in the list of medicines that have margin control and may be purchased within public budget. If the reference pricing is based on international comparison with the prices in mainly east European countries. Coverage of government was 13% of the Ukrainian pharmaceutical market. The reimbursement system of Turkey has been changed numerous times and the discount rates has incrementally risen. Ukraine has just began implementing pricing and reimbursement for medicines. It is understood that Turkey has been done policies already but Ukraine has just began implementations. Our study shows impact of Turkish reforms and expected from Ukraine.

PHP344

HEALTH PROFESSIONALS INVOLVEMENT IN POLITICS A MEANS TO IMPROVE HEALTHCARE DELIVERY AND HEALTHCARE LEGISLATION FOR HEALTHCARE SEEKERS IN AFRICA
Odenigbo AO
University of Nigeria Nsukka, Nsukka, Nigeria

OBJECTIVES: Health Professionals in Africa in an attempt to improve healthcare delivery have brought up well thought out ways to offer better health care service, but for their lack of involvement in Politics and Legislation in their countries, efforts to implement their proposals have been met with black walls. The Objective of this conceptual paper is to emphasize the need for Healthcare providers to be involved in Policy making in their countries, to champion health care policies that will improve healthcare delivery. METHODS: Using Nigeria as case study, I sort the views of several health professionals through their articles on improving Healthcare delivery in Nigeria published in popular Journals and magazines. I consulted magazines and Journals from more advanced countries to seek out ways through which they have improved their health care system. RESULTS: Of all the views presented by these health professionals (Pharmacist and Medical Doctors), most pointed towards the role of the government in improving the healthcare sector, others suggested a need for health professionals to be involved in Politics without emphasizing on it. While in my analysis of the systems in the developed countries, I discovered that healthcare providers were involved in the government not as executive but as legislature, this way they sponsor health care related bills and policies and were able to improve the value of healthcare delivery. CONCLUSIONS: To improve healthcare delivery and patient care in Africa, Health care givers (pharmacist and doctors) should be part of the countries policy makers (legislatures) so as to drive the needed transformation in the health sector.

PHP345

HEALTH CARE COST AND POLICY AND COST AFTER EARTHQUAKE IN NEPAL
Subedi N1, Poudel R2
1College of Medical Sciences, Kathmandu University, Chitwan, Nepal, 2BP Koirala Institute of Health Sciences, Dhanal, Nepal

Nepal is a topographically vulnerable country for many life threatening disasters like earthquake, landslide, avalanche, floods etc. Health care policy should focus on the disaster management plan and quick relief programs following major disasters. According to National census in 2011, 8515 people have been killed and 17,868 left injured. Nepal’s earthquake economic toll is massive in the health sector too. Many hospitals